May 2021

Press Release
RepliCel Launches Testing of Dermal Injector Units
Initial units delivered and first phase of functional testing nearly completeVANCOUVER, BC, CANADA – 25...
Press Release
RepliCel Launches Preparations for Second Skin Rejuvenation and Tendon Regeneration Clinical Studies
Clinical research organization, Accerise Inc., has been retained to work with RepliCel and its other...
Press Release
RepliCel Announces Appointment of Leading Dermatologist in Japan as Clinical Advisor
Professor Akimichi Morita, Vice Director of Nagoya City University Hospital, will lead RepliCel’s Skin Rejuvenation...
Press Release
RepliCel Launches the Next Stage of a Research Project with the University of British Columbia to Build World-Class Hair Follicle Cell Data Map
Early identification of unique cell markers is expected to have valuable impact on patents, clinical...
Press Release
RepliCel Announces Record Year in Patents Granted
Patents granted in the United States, China, South Korea, Japan, Israel and New Zealand for...
Press Release
RepliCel Announces Appointment of Leading Sports Medicine Expert as Orthopedics Clinical Advisor (Japan)
Professor Tsukasa Kumai, member of the Japan’s Olympic Committee Medical and Scientific Staff, will lead...

The information in these press releases is historical in nature, has not been updated, and is current only to the date indicated in the particular press release. This information may no longer be accurate and therefore you should not rely on the information contained in these press releases. To the extent permitted by law, RepliCel Life Sciences Inc. and its employees, agents and consultants exclude all liability for any loss or damage arising from the use of, or reliance on, any such information, whether or not caused by any negligent act or omission.

Please note that any opinion, estimates or forecasts made by the authors of these statements are theirs alone and do not represent opinions, forecasts or predictions of RepliCel Life Sciences Inc. or its management. RepliCel Life Sciences Inc. does not, by its reference or distribution of these links imply its endorsement of, or concurrence with, such information, conclusions or recommendations.